Idera Pharmaceuticals Inc
NASDAQ:IDRA
Intrinsic Value
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indica... [ Read More ]
The intrinsic value of one IDRA stock under the Base Case scenario is 0.193 USD. Compared to the current market price of 7.225 USD, Idera Pharmaceuticals Inc is Overvalued by 97%.
Valuation Backtest
Idera Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling IDRA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Idera Pharmaceuticals Inc
Current Assets | 17.9m |
Cash & Short-Term Investments | 12m |
Receivables | 4.2m |
Other Current Assets | 1.6m |
Non-Current Assets | 83.2m |
PP&E | 544k |
Intangibles | 82.7m |
Current Liabilities | 21.4m |
Accounts Payable | 5.2m |
Accrued Liabilities | 10.1m |
Other Current Liabilities | 6.1m |
Non-Current Liabilities | 40.8m |
Other Non-Current Liabilities | 40.8m |
Earnings Waterfall
Idera Pharmaceuticals Inc
Revenue
|
4.9m
USD
|
Operating Expenses
|
-24.4m
USD
|
Operating Income
|
-19.5m
USD
|
Other Expenses
|
-3.8m
USD
|
Net Income
|
-23.4m
USD
|
Free Cash Flow Analysis
Idera Pharmaceuticals Inc
IDRA Profitability Score
Profitability Due Diligence
Idera Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Idera Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
IDRA Solvency Score
Solvency Due Diligence
Idera Pharmaceuticals Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Idera Pharmaceuticals Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IDRA Price Targets Summary
Idera Pharmaceuticals Inc
Ownership
IDRA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IDRA Price
Idera Pharmaceuticals Inc
Average Annual Return | 0.92% |
Standard Deviation of Annual Returns | 105.02% |
Max Drawdown | -96% |
Market Capitalization | 450.1m USD |
Shares Outstanding | 62 296 900 |
Percentage of Shares Shorted | 1.04% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company is headquartered in Exton, Pennsylvania and currently employs 13 full-time employees. The firm designed and is developing tilsotolimod, an investigational Toll-like receptor 9 agonist, for the treatment of advanced solid tumors. Its lead investigational product, tilsotolimod, demonstrated activity in various pre-clinical models and is in clinical development across several oncology indications. These indications include anti-PD-1 refractory advanced melanoma, microsatellite-stable colorectal cancer (MSS-CRC, phase II), and recurrent/metastatic head & neck squamous cell carcinoma (HNSCC, phase I/II). Tilsotolimod is used for the treatment of anti-PD-1 refractory melanoma, in combination with ipilimumab, as well as for the treatment of stage IIb-IV melanoma. Its clinical trials include ILLUMINATE-204, ILLUMINATE-206 and ILLUMINATE-101.
Contact
IPO
Employees
Officers
The intrinsic value of one IDRA stock under the Base Case scenario is 0.193 USD.
Compared to the current market price of 7.225 USD, Idera Pharmaceuticals Inc is Overvalued by 97%.